Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Bottom Line: The time to first confirmed relapse was increased with ponesimod compared with placebo.Once-daily treatment with ponesimod 10, 20 or 40 mg significantly reduced the number of new T1 Gd+ lesions and showed a beneficial effect on clinical endpoints.NCT01006265.
Affiliation: Department of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden.Show MeSH
Related in: MedlinePlus
Mentions: Of the 621 patients screened, 464 were randomised between October 2009 and November 2010 to receive ponesimod 10, 20 or 40 mg, or placebo. Patient disposition is summarised in figure 2. In the ponesimod 10, 20 and 40 mg groups, 16.7%, 13.2% and 21.0% of patients prematurely discontinued treatment, respectively, compared with 9.1% of patients receiving placebo. Demographic and baseline disease characteristics were generally similar across treatment groups (table 1).
Affiliation: Department of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden.